APUS (Apimeds Pharmaceuticals Us) ROCE %: -97.68% (As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us ROCE %?

Apimeds Pharmaceuticals Us APUS -2.04% 14 ROCE % is -97.68% as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Apimeds Pharmaceuticals Us's annualized ROCE % for the quarter that ended in Mar. 2026 was -97.68%.

Apimeds Pharmaceuticals Us  (AMEX:APUS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Apimeds Pharmaceuticals Us ROCE % Related Terms

Apimeds Pharmaceuticals Us ROCE % Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us ROCE % Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-632.92 0.00 0.00 0.00 -7.50

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -256.59 -79.33 -4.65 -97.68
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us ROCE % Calculation

Apimeds Pharmaceuticals Us's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-5.718/( ( (0.013 - 1.024) + (164.184 - 10.706) )/ 2 )
=-5.718/( (-1.011+153.478)/ 2 )
=-5.718/76.2335
=-7.50 %

Apimeds Pharmaceuticals Us's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-136.8/( ( (164.184 - 10.706) + (141.219 - 14.585) )/ 2 )
=-136.8/( ( 153.478 + 126.634 )/ 2 )
=-136.8/140.056
=-97.68 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -97.68% mean?
Apimeds Pharmaceuticals Us (APUS) has a ROCE % of -97.68% as of Mar. 2026.
Is Apimeds Pharmaceuticals Us' ROCE % too high?
Apimeds Pharmaceuticals Us' current ROCE % is -97.68%. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' ROCE % compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' ROCE % of -97.68% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current ROCE % is -97.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current ROCE % of -97.68%. The current ROCE % is -97.68%. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current ROCE % is -97.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price